
    
      A total of 84 HCC patients who are failure from the first line Sorafenib or lenvatinib
      treatment will be randomized to two treatment arms using a 1:1 ratio: SBRT + PD-1 arm or PD-1
      alone arm.

      Patients in both arms will receive sintilimab administered intravenously at 200 mg every 3
      weeks. Stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed
      dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is
      administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of
      sintilimab will be given within 4-6 weeks after completion of SBRT.
    
  